UCon Treatment of the Symptoms of Faecal Incontinence (FI)

NCT ID: NCT05864807

Last Updated: 2025-10-01

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2025-12-01

Brief Summary

UCon is a medical device for treatment of the symptoms of overactive bladder and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder/bowel musculature e.g., suppress undesired bladder/bowel activity to relieve the symptoms of the patient. This clinical investigation is designed as a single-arm, prospective, single-centre, early feasibility study.

Detailed Description

The overall purpose of the current clinical investigation is to evaluate the medical device (UCon) with respect to initial safety and device performance in a cohort of Spanish patients with FI over a treatment period of 4 weeks.

Conditions

Faecal Incontinence; Faecal Incontinence With Faecal Urgency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Interventional arm

Electrical stimulation to the dorsal genital nerve.

Group Type: EXPERIMENTAL

UCon

Intervention Type: DEVICE

The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon

Interventions

UCon

The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Participant is ≥ 18 years of age.

2. Participant is showing symptoms of FI.

3. Participant is able to communicate, provide feedback, understand and follow instructions during the course of the investigation, including using the device at home.

Exclusion Criteria

1. Participant is medically unstable (acute illness or complication of a chronic condition that might affect the participants´ participation in the investigation).

2. Participant has an active infection in the genital area.

3. Participant has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).

4. Participant is pregnant, nursing or planning a pregnancy (to be confirmed with a negative pregnancy test). Women of childbearing potential must maintain effective contraception* during the interventional period judged by the investigator.

5. Participant is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug trial or medical device investigation within four weeks to enrolment.

6. Participant has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation, e.g., denervated patients and severe diabetic neuropathy.

7. Participant is currently receiving cancer treatment.

8. Participant has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.

9. Participant does not speak and understand Spanish.

• The following contraception is considered effective: Intrauterine device, hormonal contraceptives such as birth control pills, implants, contraceptive patch, vaginal ring, and contraceptive injection.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InnoCon Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eloy Espin Basany, MD

Role: PRINCIPAL_INVESTIGATOR

Vall d'Hebron University Hospital, 119, 08035 Barcelona, Spanien

Locations

Vall d'Hebron University Hospital

Barcelona, , Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Dianna Mærsk Knudsen

Role: CONTACT

dmk@innoconmedical.dk

+4540517712

Facility Contacts

Eloy Espin Basany, MD

Role: primary

espin@vhebron.net

676531898 ext. +34

Other Identifiers

ES_FEAS_01

Identifier Type: -

Identifier Source: org_study_id